FLD-103: A Non-invasive Treatment for Basal Cell Carcinoma with the Potential to Change Lives
Basal cell carcinoma (BCC) is the most common skin cancer and the most frequent form of all cancers. In North America, 3.6 million cases are diagnosed each year. BCC results from the uncontrolled growth of skin cells, predominantly in long-term sun-exposed areas of the body. Patients affected by BCC commonly present lesions on the face, neck, scalp and arms.
The standard of care for BCC is surgical removal or excision, notably by performing the Mohs surgery, a procedure that involves cutting away layers of skin until there is no evidence of cancer. Surgical procedures frequently result in wounds that can take up to several months/years to heal and can leave permanent scars on visible areas of the body. Patients with BCC have a higher likelihood of developing additional lesions or multiple BCC lesions, necessitating repeated surgeries. There are no effective non-surgical treatments available, leaving patients to endure considerable preoperative stress, psychological trauma, and extended recovery periods.
Feldan Therapeutics is developing FLD-103, an efficient, non-surgical approach to treat BCC. This first-in-class non-invasive intralesional treatment selectively targets BCC cells by disrupting an intracellular component involved in the pathophysiology of the disease. By minimizing side effects, avoiding scarring and the need for postoperative recovery, FLD-103 has the potential to become a minimally invasive first-line option and life-changing treatment for patients suffering from BCCs.
The standard of care for BCC is surgical removal or excision, notably by performing the Mohs surgery, a procedure that involves cutting away layers of skin until there is no evidence of cancer. Surgical procedures frequently result in wounds that can take up to several months/years to heal and can leave permanent scars on visible areas of the body. Patients with BCC have a higher likelihood of developing additional lesions or multiple BCC lesions, necessitating repeated surgeries. There are no effective non-surgical treatments available, leaving patients to endure considerable preoperative stress, psychological trauma, and extended recovery periods.
Feldan Therapeutics is developing FLD-103, an efficient, non-surgical approach to treat BCC. This first-in-class non-invasive intralesional treatment selectively targets BCC cells by disrupting an intracellular component involved in the pathophysiology of the disease. By minimizing side effects, avoiding scarring and the need for postoperative recovery, FLD-103 has the potential to become a minimally invasive first-line option and life-changing treatment for patients suffering from BCCs.
